What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders
Vera Therapeutics (VERA) reported a significant widening of net losses in Q2 2026 and the first half of 2026, reaching US$109.47 million and US$230.51 million respectively, leading to increased cash burn and pressure on per-share results. This performance highlights the high costs associated with developing its drug TRUTAKNA and the broader atacicept program, raising concerns about funding risk and potential dilution. Despite the financial challenges, the company's investment narrative hinges on the eventual commercial viability of TRUTAKNA and successful navigation of regulatory hurdles.
Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics
Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is 5 percent or less of the class.
Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?
Vera Therapeutics (VERA) received accelerated FDA approval for TRUTAKNA for IgA nephropathy, but its share price has fallen recently despite strong long-term returns. The company is currently loss-making and trades at a P/B ratio of 5.4x, which is below peers but above the broader biotech industry. A Simply Wall St DCF model suggests the stock is significantly undervalued compared to its estimated future cash flow value.
Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock
Marshall Fordyce, CEO of Vera Therapeutics, sold $679,747 worth of Class A Common Stock on May 12, 2026, after exercising stock options. These transactions were executed under a pre-arranged trading plan, and he now directly owns 235,244 shares and holds 590,551 stock options. The company recently reported Q2 2026 financial results, received accelerated FDA approval for Trutakna, and saw several analyst rating adjustments.
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 46,250 shares of the company’s Class A Common Stock for approximately $1.96 million on July 7, 2026, while concurrently acquiring the same number of shares through stock option exercises. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, with the stock price having declined significantly since the transactions. The company recently received accelerated FDA approval for its drug Trutakna and reported Q2 2026 financial results showing a narrower loss per share than estimated.
Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise
Vera Therapeutics' President and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares on June 23, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, with the shares sold at a weighted-average price of $37.9311 for 18,412 shares and $38.43 for the remaining 88 shares. This transaction was disclosed in an amended Form 4 filing correcting previous beneficial ownership amounts.
Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan
Vera Therapeutics (VERA) CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares in open-market transactions on May 12, 2026. The sales, totaling approximately $680K in gross proceeds, were executed under a pre-approved Rule 10b5-1 trading plan adopted on January 9, 2026. After these transactions, Fordyce beneficially owns 590,551 stock options and 235,244 shares of Class A Common Stock directly.
Vera Therapeutics president and CEO Marshall Fordyce sells $701,769 in stock
Vera Therapeutics president and CEO Marshall Fordyce sold 18,500 shares of Class A Common Stock for $701,769 on June 23, 2026, as part of a pre-arranged trading plan, while also exercising options for an equal number of shares. The company, valued at $2.16 billion, has a "Weak" financial health rating due to burning through cash, despite recent FDA approval for Trutakna and varying analyst price targets. Following these transactions, Fordyce holds 235,244 shares and 572,051 stock options.
Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock
Vera Therapeutics President and CEO Marshall Fordyce sold approximately $1.96 million worth of company stock through a pre-arranged trading plan, while also exercising stock options. The company's stock has since declined by over 40% year-to-date. These transactions follow recent financial results, FDA approval for its drug Trutakna, and updated analyst ratings.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards of non-qualified stock options and restricted stock units (RSUs) to its new Chief Regulatory Officer, Nancy Bowman, and two other new employees. These grants were made under the company's 2024 Inducement Plan and approved by the Compensation Committee as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs have specific exercise prices and vesting schedules over four years, subject to continued employment.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement grants of non-qualified stock options and restricted stock units (RSUs) to new employees, including its new Chief Regulatory Officer, Nancy Bowman, M.D., Ph.D. These grants, made under the company's 2024 Inducement Plan, are consistent with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize continued employment. The awards vest over four years, subject to continuous service.
State Street Corporation (VERA) discloses 4.1M-share stake in Vera Therapeutics
State Street Corporation has reported a beneficial ownership of 4,148,786 shares of Vera Therapeutics Inc. common stock, which represents a 5.8% stake in the company. The filing indicates that State Street holds shared voting power over 3,996,044 shares and shared dispositive power over all 4,148,786 shares, with no sole voting or dispositive power. This investment is managed through various investment adviser subsidiaries, including SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Vera Therapeutics grants equity inducement awards to new hires
Vera Therapeutics Inc (NASDAQ: VERA) granted inducement equity awards to three new employees, including Chief Regulatory Officer Nancy Bowman, under Nasdaq Listing Rule 5635(c)(4). The awards, consisting of stock options and RSUs, are designed to attract key talent and vest over four years subject to continued service. This move aligns with the company's strategy to bolster its regulatory and operational capabilities, particularly for its commercial-stage product TRUTAKNA™.
Equity awards for Vera Therapeutics (VERA) Chief Regulatory Officer
Vera Therapeutics (VERA) Chief Regulatory Officer, Nancy Lee Boman, received equity awards comprising 63,011 stock options with an exercise price of $32.23 and 44,987 restricted stock units (RSUs) under the company's 2024 Inducement Plan. These awards are subject to vesting schedules based on continuous service, with the options expiring in 2036 and RSUs vesting quarterly from 2027 to 2030. The Form 4 filing indicates these grants were not part of a Rule 10b5-1 trading plan.
BlackRock (NYSE: BLK) discloses 5.34M-share Vera Therapeutics (VERA) stake
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,340,522 Class A shares of Vera Therapeutics, Inc. This stake represents 7.4% of Vera Therapeutics' outstanding Class A shares. BlackRock primarily holds sole voting power over 5,247,811 shares and sole dispositive power over 5,340,522 shares, with no individual client owning more than five percent of Vera's common shares.
The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA’s Accelerated FDA Approval - Learn Why
Vera Therapeutics received accelerated FDA approval for TRUTAKNA (atacicept-vymj) to treat IgA nephropathy, targeting both BAFF and APRIL. This approval shifts the investment focus to the commercial launch, conversion to full approval, and safety management. Investors are weighing the potential for TRUTAKNA to become a durable franchise against the inherent clinical and regulatory uncertainties of accelerated approval.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement grants consisting of non-qualified stock options and restricted stock units to eight new employees. These awards are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. The stock options and RSUs will vest over four years, subject to continued employment with the company.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Inc. announced inducement awards for eight new employees, consisting of non-qualified stock options for 32,100 shares and restricted stock units for 16,050 shares. These awards, granted on July 6, 2026, under the company's 2024 Inducement Plan, are intended to be a material inducement for their employment as per Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $40.13 and both types of awards vest over four years, subject to continued employment.
New Vera Therapeutics employees receive $40.13 stock options in inducement plan
Vera Therapeutics announced that its Board Compensation Committee granted inducement equity awards to eight new employees on July 6, 2026. These awards include non-qualified stock options for 32,100 Class A shares with an exercise price of $40.13 and RSUs for 16,050 Class A shares, both vesting over four years. The grants are in accordance with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced?
Vera Therapeutics (VERA) has received accelerated FDA approval for TRUTAKNA, its first commercial product for primary IgA nephropathy. Despite a year-to-date share price decline of 12.73%, the company has seen a 1-month rebound of 33.39% following the approval and a 74.25% one-year return. While its price-to-book ratio of 6.1x suggests it's expensive compared to the broader US Biotechs sector, internal fair value estimates and discounted cash flow models suggest the stock might be undervalued.
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million
Vera Therapeutics CEO Fordyce Marshall sold approximately $1.96 million worth of Class A Common Stock on July 7, 2026, under a pre-arranged trading plan. Despite the sale, the stock is considered undervalued by InvestingPro, and the company recently received FDA approval for its drug Trutakna for IgA nephropathy, leading to several analyst price target increases. Marshall still holds a substantial number of direct and indirect shares in the biotech company.
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million
Vera Therapeutics CEO Fordyce Marshall sold Class A Common Stock valued at approximately $1.96 million on July 7, 2026, through a pre-arranged trading plan. Despite these sales, Marshall retains a significant direct and indirect stake in the company. This news follows Vera Therapeutics' recent accelerated FDA approval for its drug Trutakna, leading to several analyst price target increases.
Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported
Vera Therapeutics CEO Marshall Fordyce reported the sale of 46,250 shares of Class A common stock on July 7, 2026, through a pre-planned trading arrangement (Rule 10b5-1(c)). The shares were sold at weighted-average prices between $40.39 and $43.97. Following these transactions, Fordyce retains significant holdings, both direct and indirect, in the company.
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics has announced that Nancy Boman, M.D., Ph.D., will take over as Chief Regulatory Officer, succeeding William Turner, who will retire and transition to a Strategic Advisor role in Q3 2026. Turner's tenure included the accelerated approval of TRUTAKNA™ for IgA nephropathy. Dr. Boman brings over 25 years of regulatory affairs experience, having held similar roles at Kyverna Therapeutics, Adicet Bio, Encoded Therapeutics, and Novartis Gene Therapies.
Vera Therapeutics (VERA) Proxy filing Summary
Vera Therapeutics (VERA) has scheduled its annual meeting for May 21, 2026, where shareholders will vote on the election of three Class II directors, the ratification of KPMG LLP as the 2026 auditor, and an advisory vote on executive compensation. Only Class A common stock holders as of March 24, 2026, are eligible to vote. The company's board consists of ten independent and one executive director, with a focus on diversity and expertise.
VERA Stock Holds Gains As CEO Trims Stake In Form 4 Sale
Vera Therapeutics Inc. (NASDAQ: VERA) stock has risen by 9.52% due to positive clinical trial progress, despite its CEO, Marshall Fordyce, selling 18,500 shares for $701,769. Fordyce still retains a significant stake of over 420,000 shares, suggesting the sale is a profit-taking move rather than a sign of diminishing confidence. The company currently faces a substantial net loss and high R&D spending, but is supported by a strong cash balance of $596.8 million and a high current ratio, providing a long runway for its developmental projects.
What's Going on with Vera Therapeutics Stock on Monday?
Vera Therapeutics Inc. (NASDAQ: VERA) stock is gaining momentum as the company awaits a key FDA decision for its rare kidney disease drug, atacicept. The FDA's action date is July 7 for accelerated approval of atacicept for IgA Nephropathy, supported by positive data from the ORIGIN 3 trial. Novartis AG (NYSE: NVS) remains a competitor with its recently approved drug Vanrafia for the same condition.
Vera Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VERA)
This article provides key financial data and analyst insights for Vera Therapeutics, Inc. (NASDAQ:VERA). It covers the stock's recent performance, analyst price targets (ranging from $35.00 to $110.00), historical highs and lows, market capitalization, upcoming earnings reports, and volatility. The company's last earnings report showed a surprise of -27.22%, and it does not pay dividends.
Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan
Vera Therapeutics (VERA) CEO Marshall Fordyce sold a total of 18,500 shares of Class A Common Stock on June 23, 2026, under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share. Following these transactions, Fordyce directly holds 198,244 shares and indirectly holds an additional 222,030 shares through a trust and a GRAT.
Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock
Fordyce Marshall, President and CEO of Vera Therapeutics, sold 18,500 shares of company stock for over $700,000, executed under a pre-arranged trading plan. This sale follows a period of strong stock performance for Vera Therapeutics, which recently announced positive regulatory developments for its Phase III ORIGIN 3 study. Analysts have reacted positively to these updates, reiterating strong ratings and price targets for the company.
Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock
Fordyce Marshall, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 18,500 shares of the company's Class A Common Stock for $701,769 on June 23, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan and occurred amidst strong stock performance, with VERA shares returning 69% over the past year. Following the sale, Marshall still holds a significant number of shares directly and indirectly, while analysts have reiterated positive ratings for the company due to regulatory developments for its drug atacicept.
Vera Therapeutics (VERA) Is Up 10.7% After Accelerated FDA Timeline For Atacicept IgAN Filing - Has The Bull Case Changed?
Vera Therapeutics recently announced an accelerated FDA timeline for the ORIGIN 3 eGFR analysis for atacicept in IgA nephropathy, supporting a planned supplemental Biologics License Application in Q4 2026. This development clarifies the regulatory pathway and could fast-track full approval, influencing the company's investment narrative. Despite the positive news, Vera Therapeutics remains loss-making with increasing operating expenses, highlighting continued execution risk and potential future funding needs.
Vera Therapeutics (VERA) Stock After FDA Trial Update Has The Valuation Gap Gone Too Far
Vera Therapeutics (VERA) is seeing investor interest after reaching an agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial. While recent stock performance shows a 7.84% rise over 7 days, it's down over 90 days and year-to-date, contrasting with strong longer-term returns. A discounted cash flow (DCF) model suggests the stock is significantly undervalued at $440.11 per share compared to its current price of $34.24, though its P/B ratio indicates it appears expensive relative to industry averages.
Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com
Fordyce Marshall, President and CEO of Vera Therapeutics, sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, through a pre-arranged trading plan. Despite the insider sale and a year-to-date decline, the stock has seen an 81% return over the past year and is considered undervalued by InvestingPro. This comes amidst recent positive analyst upgrades and strategic board appointments for the company.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement grants to ten new employees, as approved by its Compensation Committee on June 2, 2026. These grants include non-qualified stock options for 28,800 shares and restricted stock units for 14,150 shares of Class A common stock, issued under the company's 2024 Inducement Plan. The awards are intended to incentivize new employees and comply with Nasdaq Listing Rule 5635(c)(4), with vesting schedules over four years contingent on continued employment.
Vera Therapeutics grants inducement awards to 10 new employees
Vera Therapeutics granted inducement awards to 10 new employees on June 2, 2026. These awards include non-qualified stock options for 28,800 shares with an exercise price of $31.26 and restricted stock units (RSUs) for 14,150 shares. The awards were approved under Nasdaq Listing Rule 5635(c)(4) and will vest over four years, aligning with employment inducement purposes.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to ten new employees, as approved by its Compensation Committee. These awards include non-qualified stock options for 28,800 shares and restricted stock units for 14,150 shares of Class A common stock, granted under the company's 2024 Inducement Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires, with vesting periods typically spanning four years.
Vera Therapeutics Grants Inducement Stock Awards to New Employees
Vera Therapeutics granted stock options for 28,800 shares and restricted stock units (RSUs) for 14,150 shares to ten new employees under its 2024 Inducement Plan. These awards, approved by the Compensation Committee in accordance with Nasdaq rules, aim to attract talent, with stock options priced at $31.26 per share, and both options and RSUs vesting over four years. The company focuses on developing treatments for immunological diseases, with lead candidate atacicept.
Vera Therapeutics gives new hires 28,800 stock option shares
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for ten new employees under its 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants comprise 28,800 stock options at an exercise price of $31.26 and 14,150 Restricted Stock Units (RSUs), both vesting over four years. These awards are intended to attract and retain talent by aligning new hires' interests with the company's long-term success.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to ten new employees, consisting of non-qualified stock options to purchase 28,800 shares and restricted stock units for 14,150 shares of Class A common stock. These grants were made under the company's 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4), and are subject to multi-year vesting schedules. Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases, including IgA nephropathy and lupus nephritis, with lead product candidate atacicept.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to ten new employees, comprising non-qualified stock options for 28,800 shares and restricted stock units for 14,150 shares of Class A common stock. These grants were made under the company's 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4), and are designed to incentivize new hires. The awards vest over four years, contingent on continued employment.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics reported the granting of inducement awards to ten new employees under its 2024 Inducement Plan, as approved by its Compensation Committee. These awards include non-qualified stock options for 28,800 shares and restricted stock units for 14,150 shares of Class A common stock, intended to incentivize new hires in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs have specific vesting schedules over four years, contingent on continued employment with the company.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced that its Compensation Committee granted inducement awards to ten new employees. These awards, consisting of non-qualified stock options and restricted stock units, were issued on June 2, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The grants involve 28,800 shares of Class A common stock through stock options and RSUs underlying 14,150 shares, with specific vesting schedules over four years.
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics announced alignment with the U.S. FDA for an earlier ORIGIN Phase 3 eGFR analysis for its drug atacicept, aiming for full approval in adults with IgA Nephropathy (IgAN). This revised schedule could lead to an sBLA submission in Q4 2026 and potential full approval in 2027, accelerating the path for what could be the first approved therapy targeting both BAFF and APRIL for IgAN. The decision is supported by positive eGFR results from the Phase 2b trial and recent discussions with the FDA.
Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading
Vera Therapeutics (VERA) has granted a stock option for 17,084 shares of Class A Common Stock to director James R. Meyers. The options have an exercise price of $34.35 per share and will expire on May 20, 2036. Vesting is contingent on continuous service, occurring on the earlier of one year from the May 21, 2026 grant date or the company's 2027 annual stockholder meeting, with full vesting also triggered by a change in control.
Director at Vera Therapeutics (VERA) receives grant of 17,084 options
Vera Therapeutics director Christy J. Oliger received a grant of 17,084 stock options at an exercise price of $34.35 per share, awarded as compensation. These options will fully vest on the earlier of the first anniversary of the grant date or the company's 2027 annual shareholder meeting, contingent on Oliger's continuous service. The options, which expire on May 20, 2036, also fully vest upon a change of control if she remains in service.
Vera Therapeutics (VERA) awards director 17,084 stock options
Vera Therapeutics director Michael Morrissey was granted 17,084 stock options for Class A Common Stock. These options have an exercise price of $34.35 and expire in 2036. They vest fully on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, contingent on continuous service, and also vest fully upon a change in control.
Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant
Vera Therapeutics director Beth C. Seidenberg was granted stock options for 17,084 Class A common shares with an exercise price of $34.35 per share. These options are part of a compensation package and will vest fully on the earlier of the first anniversary of the grant date or the company's 2027 annual stockholder meeting, provided continuous service. Full vesting also occurs upon a change in control if she remains in service.
[8-K] Vera Therapeutics, Inc. Reports Material Event
Vera Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders. Shareholders elected three Class II directors, ratified KPMG LLP as the independent registered public accounting firm, and approved executive compensation in an advisory vote. The company detailed the voting results for each proposal.
Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike
Vera Therapeutics director Scott W. Morrison was granted 17,084 stock options with an exercise price of $34.35 per share. These options vest upon the earlier of the first anniversary of the grant date, the 2027 annual stockholder meeting, or a change in control, contingent on his continued service. Following this grant, Morrison directly holds options for 17,084 shares.
